Yang Jing, Liao Dongxue, He Lanxin, Fan Wenxing
Department of Nephrology, the First Affiliated Department of Kunming Medical University, 295 Xichang Road, Wuhua District, Kunming City, 650032, Yunnan Province, China.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 25. doi: 10.1007/s00210-025-04164-1.
The therapeutic effect of exosomes (Exo) secreted by the Puerarin-treated umbilical cord mesenchymal stem cells (UC-MSC) on chronic renal failure (CRF) was explored. UC-MSC were treated by Puerarin, or transfected by lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) overexpression vectors, or both. HK-2 cells were treated with LPS/HO to establish the CRF cell model. The CRF rat model was constructed by adenine administration. Exo derived from UC-MSC were used to treat the CRF cell and rat models. The therapeutic effect of the Puerarin-treated UC-MSC-derived Exo on CRF was evaluated by a series of logical tests. NEAT1 had binding sites for miR-342-3p. miR-342-3p in the Puerarin-treated UC-MSC-derived Exo was increased. miR-342-3p in the NEAT1-overexpressed and Puerarin-treated UC-MSC-derived Exo was lower than that in the Puerarin-treated UC-MSC-derived Exo. The CRF cell model treated by the Puerarin-treated UC-MSC-derived Exo expressed higher miR-342-3p, and lower TGF-β1, SMAD2/3, Cleaved-caspase-1, GSDMD-N, IL-1β and IL-18. The relieved renal injury, up-regulated renal miR-342-3p, down-regulated renal TGF-β1, SMAD2/3, Cleaved-caspase-1 and GSDMD-N, and decreased serum creatinine and blood urea nitrogen were found in the CRF rat model treated by the Puerarin-treated UC-MSC-derived Exo. However, compared to the CRF cell and rat models treated by the Puerarin-treated UC-MSC-derived Exo, those treated by the NEAT1-overexpressed and Puerarin-treated UC-MSC-derived Exo showed the opposite results. Puerarin elevates exosomal miR-342-3p by suppressing NEAT1 in UC-MSC, thereby inactivating the TGF-β1/SMAD pathway in renal tubular epithelial cells to alleviate pyroptosis in CRF. The Puerarin-treated UC-MSC-derived Exo may be useful in treating CRF.
探讨了葛根素处理的脐带间充质干细胞(UC-MSC)分泌的外泌体(Exo)对慢性肾衰竭(CRF)的治疗作用。UC-MSC用葛根素处理,或用lncRNA核旁斑组装转录本1(NEAT1)过表达载体转染,或两者兼用。HK-2细胞用LPS/HO处理以建立CRF细胞模型。通过给予腺嘌呤构建CRF大鼠模型。源自UC-MSC的Exo用于治疗CRF细胞和大鼠模型。通过一系列逻辑测试评估葛根素处理的UC-MSC衍生的Exo对CRF的治疗效果。NEAT1具有miR-342-3p的结合位点。葛根素处理的UC-MSC衍生的Exo中的miR-342-3p增加。NEAT1过表达且经葛根素处理的UC-MSC衍生的Exo中的miR-342-3p低于葛根素处理的UC-MSC衍生的Exo中的miR-342-3p。经葛根素处理的UC-MSC衍生的Exo处理的CRF细胞模型表达较高的miR-342-3p,以及较低的TGF-β1、SMAD2/3、裂解的半胱天冬酶-1、GSDMD-N、IL-1β和IL-18。在经葛根素处理的UC-MSC衍生的Exo处理的CRF大鼠模型中发现肾损伤减轻、肾miR-342-3p上调、肾TGF-β1、SMAD2/3、裂解的半胱天冬酶-1和GSDMD-N下调,以及血清肌酐和血尿素氮降低。然而,与经葛根素处理的UC-MSC衍生的Exo处理的CRF细胞和大鼠模型相比,经NEAT1过表达且经葛根素处理的UC-MSC衍生的Exo处理的模型显示出相反的结果。葛根素通过抑制UC-MSC中的NEAT1来提高外泌体miR-342-3p,从而使肾小管上皮细胞中的TGF-β1/SMAD途径失活,以减轻CRF中的细胞焦亡。葛根素处理的UC-MSC衍生的Exo可能对治疗CRF有用。